Zacks Research Analysts Lower Earnings Estimates for Amarin

Amarin Corporation PLC (NASDAQ:AMRN) – Research analysts at Zacks Research reduced their FY2025 EPS estimates for shares of Amarin in a research note issued to investors on Monday, December 22nd. Zacks Research analyst Team now anticipates that the biopharmaceutical company will earn ($2.03) per share for the year, down from their previous estimate of ($1.97). Zacks Research has a “Hold” rating on the stock. The consensus estimate for Amarin’s current full-year earnings is ($0.15) per share. Zacks Research also issued estimates for Amarin’s Q4 2026 earnings at ($1.69) EPS, FY2026 earnings at ($3.86) EPS, Q2 2027 earnings at ($0.03) EPS and FY2027 earnings at ($3.41) EPS.

Other equities research analysts have also recently issued research reports about the company. Wall Street Zen cut Amarin from a “strong-buy” rating to a “buy” rating in a research note on Friday, November 28th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Amarin in a report on Wednesday, October 8th. One analyst has rated the stock with a Hold rating and two have given a Sell rating to the company. Based on data from MarketBeat, the stock currently has an average rating of “Sell” and a consensus price target of $12.00.

Amarin Stock Up 0.4%

Shares of NASDAQ:AMRN opened at $13.66 on Wednesday. The firm has a market cap of $283.99 million, a P/E ratio of -5.49 and a beta of 0.71. Amarin has a 12-month low of $7.08 and a 12-month high of $20.90. The business has a fifty day simple moving average of $16.32 and a 200 day simple moving average of $15.85.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently made changes to their positions in AMRN. Banque Cantonale Vaudoise acquired a new stake in Amarin during the third quarter worth approximately $32,000. GPS Wealth Strategies Group LLC bought a new position in shares of Amarin during the 2nd quarter worth approximately $32,000. Headlands Technologies LLC bought a new position in shares of Amarin during the 2nd quarter worth approximately $44,000. Northwestern Mutual Wealth Management Co. grew its position in shares of Amarin by 1,816.7% during the 3rd quarter. Northwestern Mutual Wealth Management Co. now owns 5,750 shares of the biopharmaceutical company’s stock worth $94,000 after buying an additional 5,450 shares during the period. Finally, Ameriprise Financial Inc. increased its stake in shares of Amarin by 13.1% in the 3rd quarter. Ameriprise Financial Inc. now owns 17,376 shares of the biopharmaceutical company’s stock valued at $285,000 after acquiring an additional 2,008 shares in the last quarter. 22.25% of the stock is owned by institutional investors and hedge funds.

Amarin Company Profile

Amarin Corporation plc is a biopharmaceutical company focused on the commercialization and development of therapeutics for cardiovascular health. Founded in 1993 and headquartered in Dublin, Ireland, the company is publicly traded on the NASDAQ under the ticker AMRN. Amarin’s primary mission is to improve cardiovascular outcomes through innovative lipid science and evidence-based therapies.

The company’s flagship product is Vascepa® (icosapent ethyl), a high-purity prescription omega-3 fatty acid approved for the treatment of severe hypertriglyceridemia and as an adjunct to statin therapy to reduce the risk of cardiovascular events.